Overexpression of LIMD2 promotes the progression of non‑small cell lung cancer

Zhang,Feifei; Qin,Shana; Xiao,Xiang; Tan,Yuefa; Hao,Peng; Xu,Yikai

doi:10.3892/ol.2019.10473

Overexpression of LIMD2 promotes the progression of non‑small cell lung cancer

Authors:
- Feifei Zhang
- Shana Qin
- Xiang Xiao
- Yuefa Tan
- Peng Hao
- Yikai Xu
View Affiliations

Affiliations: Department of Imaging Diagnostic Center, Nanfang Hospital of Southern Medical University, Guangzhou, Guangdong 510515, P.R. China, PET/CT Center, Inner Mongolia People's Hospital, Hohhot, Inner Mongolia 010017, P.R. China
Published online on: June 12, 2019 https://doi.org/10.3892/ol.2019.10473
Pages: 2073-2081

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

LIM domain containing 2 (LIMD2) is a small LIM‑only protein that has been demonstrated to promote tumor progression; however, the expression and function of LIMD2 in non‑small cell lung cancer (NSCLC) has not previously been reported. In the present study, reverse transcription‑quantitative PCR and western blot analysis were conducted to examine the mRNA and protein expression levels of LIMD2. Cell Counting Kit‑8, Transwell and wound‑healing assays were performed in order to examine cell proliferation, invasion and migration, respectively. The data revealed that the LIMD2 expression levels were significantly increased in NSCLC tissues and cell lines, compared with adjacent non‑tumor tissues and normal lung epithelial cells, respectively. In addition, the high expression of LIMD2 was significantly associated with lymph node metastasis, distant metastasis and advanced clinical stage in NSCLC. The patients with NSCLC with a high expression of LIMD2 exhibited shorter survival times than those with low LIMD2 expression. The knockdown of LIMD2 caused remarkable decreases in NSCLC cell proliferation, migration and invasion. Bioinformatics analysis and luciferase reporter gene assay data further confirmed that LIMD2 was a direct target gene of microRNA‑124 (miR‑124), a well‑known tumor suppressor in NSCLC. The expression of LIMD2 was negatively regulated by miR‑124 in NSCLC cells. In addition, miR‑124 was downregulated in NSCLC tissues compared with adjacent non‑tumor tissues, and an inverse correlation was observed between the expression of LIMD2 and miR‑124 in NSCLC tissues. In conclusion, the present study demonstrates that LIMD2 serves an oncogenic role in NSCLC, suggesting that it may be used as a potential therapeutic target for the treatment of NSCLC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
2	Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J and Jemal A: Global cancer statistics 2012. CA Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
3	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
4	Landi L and Cappuzzo F: Pharmacotherapy targeting the EGFR oncogene in NSCLC. Expert Opin Pharmacother. 15:2293–2305. 2014. View Article : Google Scholar : PubMed/NCBI
5	Markou A, Sourvinou I, Vorkas PA, Yousef GM and Lianidou E: Clinical evaluation of microRNA expression profiling in non small cell lung cancer. Lung Cancer. 81:388–396. 2013. View Article : Google Scholar : PubMed/NCBI
6	Peng H, Talebzadeh-Farrooji M, Osborne MJ, Prokop JW, McDonald PC, Karar J, Hou Z, He M, Kebebew E, Orntoft T, et al: LIMD2 is a small LIM-only protein overexpressed in metastatic lesions that regulates cell motility and tumor progression by directly binding to and activating the integrin-linked kinase. Cancer Res. 74:1390–1403. 2014. View Article : Google Scholar : PubMed/NCBI
7	Cerutti JM, Oler G, Michaluart P Jr, Delcelo R, Beaty RM, Shoemaker J and Riggins GJ: Molecular profiling of matched samples identifies biomarkers of papillary thyroid carcinoma lymph node metastasis. Cancer Res. 67:7885–7892. 2007. View Article : Google Scholar : PubMed/NCBI
8	Ambros V: The functions of animal microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
9	Moss EG: MicroRNAs: Hidden in the genome. Curr Biol. 12:R138–R140. 2002. View Article : Google Scholar : PubMed/NCBI
10	John B, Enright AJ, Aravin A, Tuschl T, Sande C and Marks DS: Human MicroRNA targets. PLoS Biol. 2:e3632004. View Article : Google Scholar : PubMed/NCBI
11	Bartel DP: MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell. 116:281–297. 2004. View Article : Google Scholar : PubMed/NCBI
12	Huang T, Wang G, Yang L, Peng B, Wen Y, Ding G and Wang Z: MiR-186 inhibits proliferation, migration, and invasion of non-small cell lung cancer cells by downregulating Yin Yang 1. Cancer Biomark. 21:221–228. 2017. View Article : Google Scholar : PubMed/NCBI
13	He M and Xue Y: MicroRNA-148a suppresses proliferation and invasion potential of non-small cell lung carcinomas via regulation of STAT3. Onco Targets Ther. 10:1353–1361. 2017. View Article : Google Scholar : PubMed/NCBI
14	Ren P, Gong F, Zhang Y, Jiang J and Zhang H: MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN. Tumour Biol. 37:3215–3225. 2016. View Article : Google Scholar : PubMed/NCBI
15	Tian W, Wang G, Liu Y, Huang Z, Zhang C, Ning K, Yu C, Shen Y, Wang M, Li Y, et al: The miR-599 promotes non-small cell lung cancer cell invasion via SATB2. Biochem Biophys Res Commun. 485:35–40. 2017. View Article : Google Scholar : PubMed/NCBI
16	Hu FY, Cao XN, Xu QZ, Huang Z, Zhang C, Ning K, Yu C, Shen Y, Wang M, Li Y, et al: iR-124 modulates gefitinib resistance through SNAI2 and STAT3 in non-small cell lung cancer. J Huazhong Univ Sci Technolog Med Sci. 36:839–845. 2016. View Article : Google Scholar : PubMed/NCBI
17	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
18	Matthews JM, Lester K, Joseph S and Curtis DJ: LIM-domain-only proteins in cancer. Nat Rev Cancer. 13:111–122. 2013. View Article : Google Scholar : PubMed/NCBI
19	Guo W, Zhang Y, Shi Y, Xi J, Fan H and Xu S: Decreased expression of miR-204 in plasma is associated with a poor prognosis in patients with non-small cell lung cancer. Int J Mol Med. 36:1720–1726. 2015. View Article : Google Scholar : PubMed/NCBI
20	Li X, Yu Z, Li Y, Liu S, Gao C, Hou X, Yao R and Cui L: The tumor suppressor miR-124 inhibits cell proliferation by targeting STAT3 and functions as a prognostic marker for postoperative NSCLC patients. Int J Oncol. 46:798–808. 2015. View Article : Google Scholar : PubMed/NCBI
21	Lin J, Xu K, Wei J, Heimberger AB, Roth JA and Ji L: MicroRNA-124 suppresses tumor cell proliferation and invasion by targeting CD164 signaling pathway in non-small cell lung cancer. J Gene Ther. 2:62016.PubMed/NCBI
22	Yang Q, Wan L, Xiao C, Hu H, Wang L, Zhao J, Lei Z and Zhang HT: Inhibition of LHX2 by miR-124 suppresses cellular migration and invasion in non-small cell lung cancer. Oncol Lett. 14:3429–3436. 2017. View Article : Google Scholar : PubMed/NCBI
23	Wang M, Meng B and Liu Y, Yu J, Chen Q and Liu Y: MiR-124 inhibits growth and enhances radiation-induced apoptosis in non-small cell lung cancer by inhibiting STAT3. Cell Physiol Biochem. 44:2017–2028. 2017. View Article : Google Scholar : PubMed/NCBI